-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BJBOnepLcWq9FtIj/ZuufvumsMu3Xp0cwDtP6DrgXF1oLb+2HmIyFO7sDVLlFxNY S/dh1DgCx5uI3WqqgckH5g== 0001013594-09-001394.txt : 20090717 0001013594-09-001394.hdr.sgml : 20090717 20090717165655 ACCESSION NUMBER: 0001013594-09-001394 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090715 FILED AS OF DATE: 20090717 DATE AS OF CHANGE: 20090717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 801 CORPORATE CENTER DRIVE STREET 2: SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 801 CORPORATE CENTER DRIVE STREET 2: SUITE 210 CITY: RALEIGH STATE: NC ZIP: 27607 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ELLIOTT ASSOCIATES, L.P. CENTRAL INDEX KEY: 0000904495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31361 FILM NUMBER: 09951326 BUSINESS ADDRESS: STREET 1: 712 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2125062999 MAIL ADDRESS: STREET 1: 712 FIFTH AVE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER NAME: FORMER CONFORMED NAME: ELLIOTT ASSOCIATES LP DATE OF NAME CHANGE: 19930513 4 1 bdsifm4-071709_1ex.xml JULY 17, 2009 X0303 4 2009-07-15 0 0001103021 BIODELIVERY SCIENCES INTERNATIONAL INC BDSI 0000904495 ELLIOTT ASSOCIATES, L.P. 712 FIFTH AVE NEW YORK NY 10019 0 0 1 0 Common Stock 2009-07-15 4 S 0 27770 6.0018 D 131374 I See Common Stock 2009-07-16 4 S 0 131374 6.8907 D 0 I See Common Stock 2009-07-16 4 S 0 15000 6.6325 D 160230 I See Elliott Associates, L.P., through its subsidiary, Manchester Securities Corp., a New York corporation ("Manchester"), has an indirect pecuniary interest in the shares of common stock of BioDelivery Sciences International, Inc. ("BDSI"), owned by CDC IV, LLC ("CDC IV"). Manchester owns a majority of the equity interest of CDC IV (but not a controlling interest). On June 4, 2009, the manager of CDC IV delegated to Manchester all of the manager's rights and authority with respect to the investment decisions relating to the equity securities of BDSI owned by CDC IV. On July 15, 2009, CDC IV sold an aggregate of 27,770 shares of Common Stock of BDSI at an average gross price per share of $6.0018. The individual trades made by CDC IV on July 15, 2009, are set forth on Exhibit 1(a) attached hereto. On July 16, 2009, CDC IV sold an aggregate of 131,374 shares of Common Stock of BDSI at an average gross price per share of $6.8907. The individual trades made by CDC IV on July 16, 2009, are set forth on Exhibit 1(b) attached hereto. Elliott Associates, L.P. indirectly owns shares of Common Stock of BDSI through its subsidiary, The Liverpool Limited Partnership, a Bermuda limited partnership. On July 16, 2009, The Liverpool Limited Partnership sold an aggregate of 15,000 shares of Common Stock of BDSI at an average gross price per share of $6.6325. The individual trades made by The Liverpool Limited Partnership on July 16, 2009, are set forth on Exhibit 1(c) attached hereto. Elliot Greenberg, VP of Braxton Associates, Inc., as GP of Elliott Capital Advisors, L.P., as GP of Elliott Associates, L.P. 2009-07-17 EX-99 2 bdsiex99-071709.htm JULY 17, 2009

EXHIBIT 1(a)

Trades on July 15, 2009 by CDC IV, LLC

Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.   Title of Security

(Instr. 3)

2. Transaction Date

(Month/
Day/
Year)

2A. Deemed   Execution   Date, if any

(Month/

Day/

Year)

3.Transaction

Code (Instr. 8)

4.   Securities Acquired

(A) or Disposed of (D)

(Instr. 3, 4 and 5)

5. Amount of
Securities Beneficially
Owned Following

Reported
Transaction(s)

(Instr. 3 and 4)

6.Ownership Form: Direct (D) or

Indirect (I)

(Instr. 4)

7.Nature of Indirect Beneficial Ownership

(Instr. 4)

 

Code

 

V

 

Amount

(A)or (D)

 

Price

 

Common Stock

7/15/09

 

S

 

1,807

D

$6.0075

157,337

I

(1)

Common Stock

7/15/09

 

S

 

2,700

D

$6.0100

154,637

I

(1)

Common Stock

7/15/09

 

S

 

400

D

$6.0200

154,237

I

(1)

Common Stock

7/15/09

 

S

 

300

D

$6.0050

153,937

I

(1)

Common Stock

7/15/09

 

S

 

22,563

D

$6.000

131,374

I

(1)

 

(1) Elliott Associates, L.P., through its subsidiary, Manchester Securities Corp., a New York corporation (“Manchester”), has an indirect pecuniary interest in the shares of common stock of BioDelivery Sciences International, Inc. (“BDSI”), owned by CDC IV, LLC (“CDC IV”). Manchester owns a majority of the equity interest of CDC IV (but not a controlling interest). On June 4, 2009, the manager of CDC IV delegated to Manchester all of the manager’s rights and authority with respect to the investment decisions relating to the equity securities of BDSI owned by CDC IV.

 

EXHIBIT 1(b)

Trades on July 16, 2009 by CDC IV, LLC

Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.   Title of Security

(Instr. 3)

2. Transaction Date

(Month/
Day/
Year)

2A. Deemed   Execution   Date, if any

(Month/

Day/

Year)

3.Transaction

Code (Instr. 8)

4.   Securities Acquired

(A) or Disposed of (D)

(Instr. 3, 4 and 5)

5. Amount of
Securities Beneficially
Owned Following

Reported
Transaction(s)

(Instr. 3 and 4)

6.Ownership Form: Direct (D) or

Indirect (I)

(Instr. 4)

7.Nature of Indirect Beneficial Ownership

(Instr. 4)

 

 

 

 

Code

 

V

 

Amount

(A)or (D)

 

Price

 

 

 

 

Common Stock

7/16/09

 

S

 

2,150

D

$6.0000

129,224

I

(1)

Common Stock

7/16/09

 

S

 

805

D

$6.0200

128,419

I

(1)

Common Stock

7/16/09

 

S

 

100

D

$6.7050

128,319

I

(1)

Common Stock

7/16/09

 

S

 

11,600

D

$6.7500

116,719

I

(1)

Common Stock

7/16/09

 

S

 

1,000

D

$6.7800

115,719

I

(1)

Common Stock

7/16/09

 

S

 

10,800

D

$6.7000

104,919

I

(1)

Common Stock

7/16/09

 

S

 

1,500

D

$6.7100

103,419

I

(1)

Common Stock

7/16/09

 

S

 

1,200

D

$6.8300

102,219

I

(1)

Common Stock

7/16/09

 

S

 

500

D

$6.8100

101,719

I

(1)

Common Stock

7/16/09

 

S

 

700

D

$6.8200

101,019

I

(1)

Common Stock

7/16/09

 

S

 

22,600

D

$6.8000

78,419

I

(1)

Common Stock

7/16/09

 

S

 

10,500

D

$6.9000

67,919

I

(1)

Common Stock

7/16/09

 

S

 

4,100

D

$6.8700

63,819

I

(1)

Common Stock

7/16/09

 

S

 

6,500

D

$6.8500

57,319

I

(1)

Common Stock

7/16/09

 

S

 

400

D

$6.8600

56,919

I

(1)

Common Stock

7/16/09

 

S

 

2,600

D

$6.8800

54,319

I

(1)

Common Stock

7/16/09

 

S

 

100

D

$6.9100

54,219

I

(1)

Common Stock

7/16/09

 

S

 

800

D

$6.9400

53,419

I

(1)

Common Stock

7/16/09

 

S

 

25,000

D

$7.0000

28,419

I

(1)

Common Stock

7/16/09

 

S

 

300

D

$7.1350

28,119

I

(1)

Common Stock

7/16/09

 

S

 

700

D

$7.1400

27,419

I

(1)

Common Stock

7/16/09

 

S

 

2,300

D

$7.1600

25,119

I

(1)

Common Stock

7/16/09

 

S

 

6,647

D

$7.1200

18,472

I

(1)

Common Stock

7/16/09

 

S

 

18,472

D

$7.1100

0

I

(1)

 

(1) Elliott Associates, L.P., through its subsidiary, Manchester Securities Corp., a New York corporation (“Manchester”), has an indirect pecuniary interest in the shares of common stock of BioDelivery Sciences International, Inc. (“BDSI”), owned by CDC IV, LLC (“CDC IV”). Manchester owns a majority of the equity interest of CDC IV (but not a controlling interest). On June 4, 2009, the manager of CDC IV delegated to Manchester all of the manager’s rights and authority with respect to the investment decisions relating to the equity securities of BDSI owned by CDC IV.

 

EXHIBIT 1(c)

Trades on July 16, 2009 by The Liverpool Limited Partnership

Table I – Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.   Title of Security

(Instr. 3)

2. Transaction Date

(Month/
Day/
Year)

2A. Deemed   Execution   Date, if any

(Month/

Day/

Year)

3.Transaction

Code (Instr. 8)

4.   Securities Acquired

(A) or Disposed of (D)

(Instr. 3, 4 and 5)

5. Amount of
Securities Beneficially
Owned Following

Reported
Transaction(s)

(Instr. 3 and 4)

6.Ownership Form: Direct (D) or

Indirect (I)

(Instr. 4)

7.Nature of Indirect Beneficial Ownership

(Instr. 4)

 

 

 

 

Code

 

V

 

Amount

(A)or (D)

 

Price

 

 

 

 

Common Stock

7/16/09

 

S

 

17

D

$6.3700

175,213

I

(1)

Common Stock

7/16/09

 

S

 

9,568

D

$6.5000

165,645

I

(1)

Common Stock

7/16/09

 

S

 

2,800

D

$6.6000

162,845

I

(1)

Common Stock

7/16/09

 

S

 

555

D

$7.1200

162,290

I

(1)

Common Stock

7/16/09

 

S

 

1,460

D

$7.1600

160,830

I

(1)

Common Stock

7/16/09

 

S

 

600

D

$7.1700

160,230

I

(1)

 

(1) Elliott Associates, L.P. indirectly owns shares of Common Stock of BDSI through its subsidiary, The Liverpool Limited Partnership, a Bermuda limited partnership.

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----